Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia

Yueting Huang, Huijian Zheng, Yuwen Zhu, Hong Yan, Jie Zha, Zhijuan Lin, Zhifeng Li, Caiyan Wang, Zhihong Fang, Xingxing Yu, Long Liu, Bing XuFrontiers in Immunology 2023 · DOI

Abstract

In summary, lack of CD28 expression defined a severely exhausted status from exhausted T cells. Accumulation of CD28- exhausted T cells was linked to occurrence of AML, and correlated to poor clinical outcome. Our data might facilitate the development of combinatory strategies to improve the efficacy of PD-1 blockade in AML.

Introduction

Immunotherapies like PD-1 blockade (e.g., pembrolizumab) have revolutionized treatment for many solid tumors by reinvigorating exhausted T cells. However, these therapies have been notably ineffective in acute myeloid leukemia (AML). T-cell exhaustion exists on a spectrum; while T cells in AML are known to be exhausted, distinguishing between cells that can be rescued by therapy and those that are irreversibly dysfunctional has been a significant challenge. This study investigates whether the loss of CD28—a critical costimulatory protein required for T-cell activation—marks a "point of no return" for T-cell dysfunction in AML.

Methods

The study utilized bone marrow (BM) samples from 42 de novo AML patients at initial diagnosis, 32 AML patients in complete remission (CR), and 15 healthy donors (HD) as a control group. Researchers employed multiparameter flow cytometry to map the landscape of T-cell phenotypes, specifically targeting exhaustion markers (PD-1, TIGIT), senescence markers (KLRG-1, CD57), and the costimulatory marker CD28. Functional assays were also performed ex vivo to measure the ability of T cells to produce cytokines (IFN-γ) and degranulate (CD107a) upon stimulation.

Results

Phenotypic Shift and CD28 Loss

A primary finding was a significant increase in the frequency of CD28-negative T cells in AML patients compared to healthy controls. This shift was evident in both CD8+ and CD4+ T cell populations, suggesting a systemic failure of costimulatory potential in the leukemic microenvironment.

Comparison of CD28- T cell subsets between healthy donors (HD) and AML patients, showing a significant increase in the CD28- population in AML.

Characterization of the "Severely Exhausted" State

The study revealed that CD28- T cells represent the most dysfunctional subset. These cells frequently co-expressed senescence markers like CD57 and KLRG1, indicating they have reached a state of permanent growth arrest. Functional assays confirmed this impairment: CD28- T cells produced significantly less IFN-γ and showed lower degranulation compared to their CD28+ counterparts.

Comprehensive phenotypic landscape of T cell exhaustion and senescence in AML, comparing memory subsets (TCM, TEM, TEMRA, Tnaive) and marker expression between HD and AML.

Crucially, while achieving complete remission improved the exhaustion status of CD28+ T cells, the "severely exhausted" CD28- population often persisted, potentially serving as a reservoir for future relapses.

Clinical Impact and Prognosis

The frequency of specific T-cell subsets at diagnosis correlated strongly with clinical outcomes. A higher frequency of CD28-TIGIT+CD8+ T cells was a significant predictor of poor response to induction chemotherapy and shorter leukemia-free survival ($P=0.046$). Additionally, in patients who achieved remission, higher frequencies of CD28-TIGIT-CD4+ T cells correlated with the presence of Minimal Residual Disease (MRD).

Discussion

The loss of CD28 appears to be a critical barrier to successful immunotherapy in AML. Because PD-1 blockade typically requires CD28 signaling to effectively reinvigorate T cells, the accumulation of CD28- cells explains why standard checkpoint inhibitors often fail in this disease. These cells lack the necessary "gas pedal" (CD28) to resume activity even after the inhibitory "brakes" (PD-1) are removed.

While limited by its retrospective nature and sample size, this study highlights a clear need for "signal 2" (costimulation) focused therapies. Future strategies might involve CD28 agonists or engineered CAR-T cells that bypass the requirement for endogenous CD28 to overcome this severe exhaustion state and improve the efficacy of existing immunotherapies.

Summary updated

Abstract

In summary, lack of CD28 expression defined a severely exhausted status from exhausted T cells. Accumulation of CD28- exhausted T cells was linked to occurrence of AML, and correlated to poor clinical outcome. Our data might facilitate the development of combinatory strategies to improve the efficacy of PD-1 blockade in AML.
BibTeX
@inproceedings{huang2023loss,
  author = {Yueting Huang and Huijian Zheng and Yuwen Zhu and Hong Yan and Jie Zha and Zhijuan Lin and Zhifeng Li and Caiyan Wang and Zhihong Fang and Xingxing Yu and Long Liu and Bing Xu},
  title = {{Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1139517},
}
Figure